Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Cefepime (BMY-28142) in Resistance Models
2026-08-19
Cefepime (BMY-28142) supports a practical bridge between β-lactam susceptibility testing, plasmid-mediated resistance analysis, and central nervous system infection research. This guide shows how to build reproducible assays while treating resistance, blood-brain barrier exposure, and neurotoxicity as separate experimental questions.
-
5-Azacytidine: DNMT Inhibitor for Cancer Research
2026-08-19
5-Azacytidine, also called 5-AzaC, is a cytosine analogue DNA methyltransferase inhibitor used to study DNA demethylation, gene reactivation, and cancer-cell responses. Its mechanism depends on nucleic-acid incorporation and DNMT trapping, while recent work shows that combination treatment with retinoic-acid agonists can reprogram disseminated cancer cells into dormancy.
-
CFDA SE Cell Tracer Kit: Practical Workflow
2026-08-18
The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for cell lineage tracing, cell proliferation studies, and related flow cytometry or microscopy workflows. It is intended for persistent covalent tracking over several days, not for short-term reversible labeling or rapid real-time dye-clearance studies.
-
Biotin-tyramide (A8011): Practical TSA Guide
2026-08-18
Biotin-tyramide (A8011) supports HRP-driven biotin deposition when conventional immunohistochemistry or in situ hybridization signals are too weak for reliable imaging. It is intended for fixed cells and tissue sections in research workflows, not as a general water-soluble labeling reagent or for diagnostic and medical use.
-
Cy3 Goat Anti-Rabbit IgG: From Biomarker to Image
2026-08-17
Discover how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody can connect quantitative HMGB1 biomarker discovery with spatial validation in immunofluorescence, IHC, and ICC. This evidence-driven guide focuses on assay architecture, controls, signal interpretation, and practical limitations rather than routine product promotion.
-
HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation
2026-08-17
The reference study identifies an LMP1–STAT5A–HDAC1/2–CEBPA pathway through which Epstein–Barr virus promotes dedifferentiation and plasticity in nasopharyngeal carcinoma. Its experiments support HDAC inhibition as a differentiation-oriented strategy for restoring CEBPA activity and reducing stem-like tumor-cell states in xenograft models.
-
CHIR-99021 for Mesodermal Organoid Signaling
2026-08-16
CHIR-99021 (CT99021) gives stem cell and organoid researchers a tunable way to interrogate GSK-3–dependent Wnt signaling, lineage commitment, and tissue organization. This workflow connects a defined small-molecule pulse with the budoid model’s epithelial–mesodermal signaling logic, while providing practical controls for dose, timing, stock handling, and morphological variability.
-
EdU Imaging Kits (Cy3): S-Phase DNA Detection
2026-08-15
EdU Imaging Kits (Cy3) provide a 5-ethynyl-2'-deoxyuridine imaging kit workflow for labeling nascent DNA without antibody-based DNA denaturation. The Cy3 click-chemistry readout supports fluorescence microscopy, flow cytometry, and controlled cell proliferation or genotoxicity studies.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Assay Strategy
2026-08-14
Learn how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody supports mechanistically rigorous immunofluorescence, IHC, and ICC workflows. This guide connects reagent selection with pathway-level interpretation using recent rheumatoid arthritis research as a practical model.
-
A-1331852: BCL-XL Inhibition in Glioblastoma
2026-08-14
A-1331852 is a selective BCL-XL inhibitor for dissecting apoptotic dependence in glioblastoma and other cancer models. This article connects BCL-XL–BIM complex disruption with apoptotic priming, assay design, and translational limitations.
-
Podophyllotoxin Workflows for HCC and Autophagy
2026-08-13
Build reproducible Podophyllotoxin assays around microtubule disruption, G2/M arrest, apoptosis, and autophagy flux. This guide distinguishes direct compound testing from mechanistically related hepatocellular carcinoma research and provides practical preparation, optimization, and troubleshooting strategies.
-
5-Azacytidine: From Demethylation to DNA Damage
2026-08-13
5-Azacytidine is more than a DNA demethylation agent: it can create DNMT-linked DNA damage and ATR-associated apoptotic signaling. This guide translates that dual biology into better assay design for leukemia and multiple myeloma research.
-
AO/PI Double Staining Kit: Practical Workflow
2026-08-12
The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates viable, apoptosis-associated, and membrane-compromised cell populations in one staining workflow. It is intended for fluorescence-based research readouts and should not be treated as a standalone molecular confirmation of apoptosis or as a non-fluorescent assay.
-
EdU Cell Proliferation Kit for RA FLS Studies
2026-08-12
Translate ARL4C-driven synoviocyte biology into a direct, non-radioactive S-phase readout with the EdU Cell Proliferation Kit (TMB). This workflow supports rheumatoid arthritis mechanism studies, genotoxicity testing assay design, and pharmacodynamic drug evaluation while highlighting controls that prevent common interpretation errors.
-
5-Azacytidine Workflows for DNA Demethylation
2026-08-11
Build more informative 5-Azacytidine experiments by separating DNA demethylation from DNA-damage-driven cytotoxicity. This workflow guide covers formulation, dose selection, orthogonal readouts, combination studies, and practical troubleshooting for leukemia and multiple myeloma models.